Efficacy of Second-Line Lenvatinib After Atezolizumab–Bevacizumab and Durvalumab–Tremelimumab in Unresectable Hepatocellular Carcinoma: Association with Prior Immunotherapy Response. - Kuzuya, Teiji; Muto, Hisanori; Tachi, Yoshihiko; Komura, Gakushi; Nakano, Takuji; Tanaka, Hiroyuki; Nakaoka, Kazunori; Funasaka, Kohei; Nagasaka, Mitsuo; Miyahara, Ryoji; Ohno, Eizaburo (Cancers, 2026)